Robert Blaustein, M.D., Ph.D.

Robert Blaustein is the Chief Medical Officer at Immutrin leading the clinical development of a novel antibody for the treatment of amyloid cardiomyopathy. During his career in the Pharma industry he has served as Chief Development Officer at Edgewise Therapeutics and spent 15+ years at Merck where he was most recently an Associate Vice President and the Atherosclerosis Section Head in the Atherosclerosis and Metabolism Clinical Research Department leading all late phase development efforts in the Atherosclerosis space. During his tenure at Merck, Dr. Blaustein contributed to clinical programs across a range of cardiovascular indications, and has led clinical development in both the atherosclerosis and heart failure spaces. He led the vericiguat development team through the completion of the Phase III VICTORIA heart failure trial and subsequent regulatory filing and global approval of vericiguat for the treatment of patients with worsening heart failure, a collaborative effort with the Bayer Company.

Dr. Blaustein obtained his undergraduate degree in Mathematics from Wesleyan University and his MD/PhD from the Albert Einstein College of Medicine. His post-graduate training included medical residency at Brigham and Women’s hospital, cardiology fellowship training at Massachusetts General Hospital, and an HHMI post-doctoral fellowship in the lab of Chris Miller in the Biochemistry Department at Brandeis University. He then joined the faculty of Tufts Medical Center as the PI of a laboratory studying ion channel proteins. At Tufts he served as an attending cardiologist in the Cardiology Division, was a faculty member in the Neuroscience and Biochemistry Departments, and was co-director of the medical school's MD-PhD Medical Scientist Training Program.